Journal of Clinical Oncology
Articles in this Issue
Temporal and regional mortality trends due to pulmonary embolism in patients with hematolymphoid malignancies in the United States from 1999 to 2020.
e19087 Background: Pulmonary embolism (PE) is a significant complication and a marker of increased mortality in patients suffering from hematolymphoid mal...
Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors.
3018 Background: ADRX-0706 is a Nectin-4 targeting ADC designed to provide an increased therapeutic window through stable conjugation of a novel microtubu...
Racial and gender disparities in the prevalence of severe ARDS among lung cancer patients.
e23088 Background: Acute Respiratory Distress Syndrome (ARDS) is a critical challenge in managing severely ill patients, especially those with lung cancer...
Beyond the numbers: Dissecting racial and gender disparities in myeloma mortality.
e19547 Background: Myeloma is a plasma cell malignancy with increasing global incidence and mortality, disproportionately affecting certain populations. W...
Decoding immune dysregulation in AML: Insights from integrated genomic and transcriptomic analysis.
6519 Background: Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy marked by abnormal proliferation of myeloid progenitor cells, often...
Tumor spatial transcriptomics and potential mechanisms of intrinsic resistance to HER2-directed therapy.
e12602 Background: Neoadjuvant dual HER2 blockade + chemotherapy (NAC) is standard of care for early-stage HER2+ breast cancer (BC), leading to pathologic...
Comparative efficacy of benzydamine and alternative mouthwashes in the management of oral mucositis: A systematic review of randomized control trials.
e24124 Background: Oral mucositis (OM) is a common complication in patients undergoing chemotherapy (CT) and radiotherapy (RT). This condition impairs nut...
Epidemiology and outcomes of sepsis in patients hospitalized with esophageal cancer: A nationwide analysis.
e16068 Background: Esophageal cancer (EC) originates in the lining of the esophagus and often necessitates hospitalization in advanced stages. Sepsis, a s...
Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA).
TPS2682 Background: FSHR is a tissue specific antigen expressed in > 55% of high-grade epithelial OVCAs with negligible FSHR expression in non-ovarian...
Potential risk factors, course of disease, and clinical outcomes of neuroendocrine prostate cancer (NEPC): A retrospective analysis.
e17051 Background: Despite the rising number of newly diagnosed neuroendocrine prostate cancer (NEPC), there is little data available on risk factors and...
Digital pathology–based AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer.
8569 Background: Accurate prediction of outcomes with anti-PD-1/PD-L1 immune checkpoint inhibition (ICI) remains a significant challenge in non-small cell...
Association of surgical intervention with 30-day re-admission and outcomes in patients hospitalized for small bowel neuroendocrine tumor-related obstruction.
e16348 Background: Small bowel neuroendocrine tumors (SBNETs) are associated with a significantly increased risk of small bowel obstruction (SBO). Althoug...
Micro-mosaicism of <i>BRAF</i> V600E oncogene in normal skin samples of patients with Erdheim-Chester disease.
e15073 Background: Erdheim-Chester disease (ECD) is a histiocyte neoplasm with frequent long bone, retroperitoneal, cardiovascular and/or central nervous...
Efficacy and safety of whole brain low dose radiotherapy combined with immune checkpoint inhibitor and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
e20060 Background: To explore the efficacy and safety of whole-brain low-dose radiotherapy combined with immune checkpoint inhibitor (ICI) and intrathecal...
Examining the impact of substance use and mental health disorders on cancer care in urban underserved communities.
e13789 Background: Substance use disorders and mental illness significantly contribute to disparities in cancer care, particularly within underserved popu...
Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial.
4500 Background: Platinum-based chemotherapy is a standard of care (SOC) for unresectable or mUC; patients (pts) ineligibl...
Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
8072 Background: The immunotherapy era has led to a resurgence of interest in surgical management of clinical Stage III non-small cell lung cancer (NSCLC)...
Mutation rate differences across populations and association with performance disparities in pathology AI diagnostic models.
1603 Background: Previous studies have established artificial intelligence (AI) algorithms to classify cancer types, providing real-time diagnostic suppor...
The paradoxical impact of depression on mortality, length of stay, and hospitalization charges in patients with prostate and bladder cancer: Using the 2021 NIS database.
e17148 Background: Depression is a prevalent comorbidity in patients with cancer, potentially influencing treatment outcomes. This study evaluates the ass...
Sex-based differences in clinical outcomes for solid tumours: A pooled IPD meta-analysis of contemporary anticancer drug trials.
11042 Background: Sex-based differences in outcomes with contemporary oncology treatments remain underexplored, creating a gap in the evidence required fo...
Changes in demographics and patterns of colon cancer in the United States: A comprehensive SEER analysis 2010–2021.
3607 Background: Over the past two decades, colon cancer has remained a leading cause of cancer-related morbidity and mortality in the United States. Chan...
First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRAS <sup>G12C</sup> -mutated non-small cell lung cancer (NSCLC) from the phase 2 portion of the KRYSTAL-7 study.
8500 Background: In the phase 2 KRYSTAL-7 study (NCT04613596), first-line ADA, a KRAS G12C inhibitor, plus PEMBRO demonstrated cli...
The impact of primary tumor resection on survival outcomes in de novo metastatic urothelial carcinoma patients: A multicenter retrospective study.
e16557 Background: De novo metastatic urothelial carcinoma (mUC) remains a challenging disease with a poor prognosis. While systemic therapy remains the c...
Epidemiological and clinical trends in common hematological malignancies in Arkansas: Arkansas Central Cancer Registry (ACCR)-based study.
e22579 Background: Arkansas ranks fifth among the US states with the highest cancer mortality rate. Since Arkansas is not a part of the Surveillance, Epid...
Complex interplay between housing insecurity and forgone care among U.S. cancer survivors.
11010 Background: One-sixth of U.S. cancer survivors experience housing insecurity, and one-fifth report delaying or forgoing care due to costs. The role...